DCGI (Drugs Controller General of India) gives restricted emergency use authorisation to BharatBiotech’s Covaxin for children between the age of 6-12 years. More details on Dynamite News:
The Drugs Controller General of India (DCGI) on Friday granted permission to Bharat Biotech to conduct clinical trials of intranasal vaccine BBV154.
The Drugs Controller General of India (DCGI) on Thursday granted conditional regular market approval for COVID-19 vaccines Covaxin and Covishield for restricted use in emergency situations in the adult population.
Indian vaccine manufacturing company Serum Institute of India (SII) has sought permission from the Drug Controller General of India (DCGI) for the production of the Russian vaccine Sputnik V in India.
The Drugs Controller General of India (DCGI) has done away with specific trials of COVID-19 vaccines that have been approved by other international regulatory bodies – a big move likely to clear the way for foreign vaccines like Pfizer and Moderna for the country’s urgent requirement.
Zydus Cadila has sought approval from the Drugs Controller General of India (DCGI) to undertake clinical trials for monoclonal antibodies cocktail that can neutralise COVID-19 infection, the pharmaceutical manufacturer informed on Thursday.
The Drugs Controller General of India (DCGI) has approved the emergency use of an anti-COVID drug – 2-deoxy-D-glucose (2-DG) – as an adjunct therapy in moderate to severe COVID-19 cases.
As India gears up for the world’s largest vaccination programme, the Drugs Controller General of India (DCGI) on Sunday quelled rumours surrounding the COVID-19 vaccines regarding impotency, rubbishing such speculations as “complete nonsense”.
Prime Minister Narendra Modi congratulated the country as Drugs Controller General of India (DCGI) granted emergency use approval to Serum Institute of India and Bharat Biotech for their COVID-19 vaccines on Sunday.
English
English
English
